Shire reports positive new data on Vpriv

Shire has reported positive new clinical trial data at the European Working Group on Gaucher Disease meeting to highlight the efficacy of its new drug Vpriv.

Results from recent studies reveal that the treatment is able to significantly improve selected markers of Gaucher-related bone disease in patients, including bone mineral density.

The drug demonstrated superior performance when compared to an established alternative, while safety data was also shown to be encouraging.

Vpriv is approved in 40 countries, including the US, EU and Israel, for use among previously treated and treatment-naive type 1 Gaucher disease patients.

Professor Ari Zimran of the Shaare Zedek Medical Center at the Hebrew University and Hadassah Medical School in Jerusalem, said: "These study results show that Vpriv is effective in treating selected markers of Gaucher-related bone disease, allowing these patients to achieve an important therapeutic goal quickly."

Last month, the company announced plans to expand its operations in San Diego, with the aim of bolstering the capabilities of its regenerative medicine business Advanced BioHealing.